Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab for migraine prevention in adults with major depressive disorder
MOH_2019-12-12_008549Phase 4Not yet recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fremanezumab in migraine and major depressive disorder (MDD) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
fremanezumab
03
Conditions
migrainemajor depressive disorder (MDD)
Beyond the preview
Go deeper on MOH_2019-12-12_008549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-12_008549.